Concept of Zhejiang Shenghua Baike Biological Co., Ltd.

(1) Concept of avian influenza: Qingdao Yibang Bioengineering Company, accounting for 38% of the shares, is a designated production enterprise of avian influenza vaccine officially approved by the Ministry of Agriculture. The company has more than 30 kinds of veterinary biological products, mainly inactivated avian influenza vaccine, including H9 subtype inactivated avian influenza vaccine, H5 and H9 bivalent inactivated avian influenza vaccine. The company's production base is located in Hongdao near Jiaozhou Bay, Qingdao. There are two GMP biological products workshops that have passed the national certification, with an annual output of 8 billion pieces of various veterinary biological products. Zhejiang Yibang Biotechnology Co., Ltd. invested by the company settled in Hangzhou Economic and Technological Development Zone, with a total investment of 654.38+0.2 billion yuan and a registered capital of 60 million yuan. After the project is completed, it is mainly engaged in the research, transformation, production and sales of animal vaccines, diagnostic reagents, monoclonal antibodies, specific antibodies, immune enhancers and adjuvants. After production, it will form an annual output of 654.38+04 billion animal vaccines. The company's net profit in the first half of 2009 was RMB 365,438+0,565,438+0,000.

(2) Veterinary pesticide faucets are equipped with advanced testing instruments and central laboratories, and the technical level is at the leading level at home and abroad.

(3) Concept of glyphosate: The company holds 565,438+0% equity of Zhejiang Baike Kaipu Chemical Co., Ltd., and its main products are: 98% iminodiacetic acid (654.38+0.5 million tons/year) and glyphosate amine salt (90%, 95% and 98% respectively, 654.38+0.5 million tons). The technical transformation project with an annual output of 5,000 tons of glyphosate is planned to invest 28.3 million yuan, with a cumulative investment of13.7 million yuan by the end of June 2009, and the project is under construction. In 2008, the company realized a net profit of 1 13508900 yuan.

(4) Xinaote: The company holds 95. 10% equity of Huzhou Xinaote Pharmaceutical Chemical Co., Ltd., and the products successfully developed by the company and put into mass production include high-purity acetylacetone, high-purity isopropyl acetate and tin methyl mercaptan, which have been recognized as national key new products and provincial high-tech products by the Ministry of Science and Technology and the State Economic and Trade Commission. The new project with an annual output of 5,000 tons of high-purity acetylacetone has been put into production, making it the largest acetylacetone producer at present. The company has a huge domestic market and actively radiates to foreign markets, and has stable international customers in Europe, America and Southeast Asia. The company lost money in 2008.